The latest advances in asthma treatment have highlighted the significance of eosinophilia and the possible role of some pro-eosinophilic mediators, like interleukins (IL) IL-5, IL-4/IL-13, and IL-33 in the disease's pathogenesis. Considering that a subgroup of patients with chronic obstructive pulmonary disease (COPD) may have blood eosinophilia akin to that seen in asthma, numerous studies in the last decade have suggested that eosinophilic COPD is a separate entity. While the exact role of blood eosinophils in the pathophysiology of COPD remains unclear, eosinophilia seems to increase the effectiveness of corticosteroid therapy. Currently, monoclonal antibodies targeting the interleukins (IL-5, IL-4, IL-13, and IL-33) or their receptors are being investigated in patients with COPD belonging in T2-high endotype. This review focuses on the mechanisms of eosinophilia in COPD, the effects of eosinophilia on disease outcome, and examines the most recent data on the use of peripheral blood eosinophilia in treating patients with COPD. Finally, we emphasize the current implication of monoclonal antibodies in COPD in the context of eosinophilic airway inflammation.

Konstantinos Bartziokas

Andriana I Papaioannou

Nikoletta Rovina

Georgia Papaiakovou

Stelios Loukides

Paschalis Steiropoulos

Pulmonary Therapy

Aims and Scope



Pulmonary Therapy is an international, open access, peer-reviewed (single-blind), and rapid publication journal. The scope of the journal is broad and will consider all scientifically sound research from pre-clinical, clinical (all phases), observational, real-world, and health outcomes research around the use of pulmonary therapies, devices, and surgical techniques.



Areas of focus include, but are not limited to: asthma; chronic obstructive pulmonary disease; idiopathic pulmonary fibrosis; pulmonary hypertension; cystic fibrosis; lung cancer; respiratory tract disorders; allergic rhinitis and other respiratory allergies; influenza, pneumococcal infection, respiratory syncytial virus and other respiratory infections; and inhalers and other device therapies.



The journal is of interest to a broad audience of pharmaceutical and healthcare professionals and publishes original research, reviews, case reports/series, trial protocols and short communications such as commentaries and editorials. Pulmonary Therapy will consider all scientifically sound research be it positive, confirmatory or negative data. Submissions are welcomed whether they relate to an international and/or a country-specific audience, something that is crucially important when researchers are trying to target more specific patient populations. This inclusive approach allows the journal to assist in the dissemination of quality research, which may be considered of insufficient interest by other journals.



Rapid Publication



The journal’s publication timelines aim for a rapid peer review of 2 weeks. If an article is accepted it will be published 3–4 weeks from acceptance. The rapid timelines are achieved through the combination of a dedicated in-house editorial team, who manage article workflow, and an extensive Editorial and Advisory Board who assist with peer review. This allows the journal to support the rapid dissemination of research, whilst still providing robust peer review. Combined with the journal’s open access model this allows for the rapid, efficient communication of the latest research and reviews, fostering the advancement of pulmonary therapies.

Open Access

All articles published by Pulmonary Therapy are open access.

Personal Service



The journal’s dedicated in-house editorial team offer a personal “concierge service” meaning authors will always have an editorial contact able to update them on the status of their manuscript.  The editorial team check all manuscripts to ensure that articles conform to the most recent COPE, GPP and ICMJE publishing guidelines. This supports the publication of ethically sound and transparent research.



Digital Features and Plain Language Summaries



Pulmonary Therapy offers a range of additional features designed to increase the visibility, readership and educational value of the journal’s content. Each article is accompanied by key summary points, giving a time-efficient overview of the content to a wide readership. Articles may be accompanied by plain language summaries to assist readers who have some knowledge of, but not in-depth expertise in, the area to understand the scientific content and overall implications of the article. The journal also provides the option to include various types of digital features including animated abstracts, video abstracts, slide decks, audio slides, instructional videos, infographics, podcasts and animations. All additional features are peer reviewed to the same high standard as the article itself. If you consider that your paper would benefit from the inclusion of a digital feature, please let us know. Our editorial team are able to create high-quality slide decks and infographics in-house, and video abstracts through our partner Research Square, and would be happy to assist in any way we can. For further information about digital features, please contact the journal editor (see ‘Contact the Journal’ for email address), and see the ‘Guidelines for digital features and plain language summaries’ document under ‘Submission guidelines’.



For examples of digital features please visit our showcase page https://springerhealthcare.com/expertise/publishing-digital-features/   



Publication Fees



Upon acceptance of an article, authors will be required to pay the mandatory Rapid Service Fee of €4500/ $5100/ £3650. The journal will consider fee discounts and waivers for developing countries and this is decided on a case by case basis.



Peer Review Process



Upon submission, manuscripts are assessed by the editorial team to ensure they fit within the aims and scope of the journal and are also checked for plagiarism. All suitable submissions are then subject to a comprehensive single-blind peer review. Reviewers are selected based on their relevant expertise and publication history in the subject area. The journal has an extensive pool of editorial and advisory board members who have been selected to assist with peer review based on the afore-mentioned criteria.



At least two extensive reviews are required to make the editorial decision, with the exception of some article types such as Commentaries, Editorials, and Letters which are generally reviewed by one member of the Editorial Board. Where reviewer recommendations are conflicted, the editorial board will be contacted for further advice and a presiding decision. Manuscripts are then either accepted, rejected or authors are required to make major or minor revisions (both reviewer comments and editorial comments may need to be addressed). Once a revised manuscript is re-submitted, it is assessed along with the responses to reviewer comments and if it has been adequately revised it will be accepted for publication. Accepted manuscripts are then copyedited and typeset by the production team before online publication. Appeals against decisions following peer review are considered on a case-by-case basis and should be sent to the journal editor.



Preprints



We encourage posting of preprints of primary research manuscripts on preprint servers, authors’ or institutional websites, and open communications between researchers whether on community preprint servers or preprint commenting platforms. Posting of preprints is not considered prior publication and will not jeopardize consideration in our journals. Authors should disclose details of preprint posting during the submission process or at any other point during consideration in one of our journals. Once the manuscript is published, it is the author’s responsibility to ensure that the preprint record is updated with a publication reference, including the DOI and a URL link to the published version of the article on the journal website.

Please follow the link for further information on preprint sharing:

https://www.springer.com/gp/authors-editors/journal-author/journal-author-helpdesk/submission/1302#c16721550



Copyright



Pulmonary Therapy's content is published open access under the Creative Commons Attribution-Noncommercial License, which allows users to read, copy, distribute, and make derivative works for non-commercial purposes from the material, as long as the author of the original work is cited. The author assigns the exclusive right to any commercial use of the article to Springer. For more information about the Creative Commons Attribution-Noncommercial License, click here: http://creativecommons.org/licenses/by-nc/4.0.



Contact



For more information about the journal, including pre-submission enquiries, please contact christopher.vautrinot@springer.com.

Pulmonary Therapy is an international, open access, peer-reviewed (single-blind), and rapid publication journal. The journal has a broad scope and considers all scientifically sound research from pre-clinical, clinical (all phases), observational, real-world, and health outcomes research related to pulmonary therapies, devices, and surgical techniques. Areas of focus include, but are not limited to: asthma; chronic obstructive pulmonary disease; idiopathic pulmonary fibrosis; pulmonary hypertension; cystic fibrosis; lung cancer; respiratory tract disorders; allergic rhinitis and other respiratory allergies; influenza, pneumococcal infection, respiratory syncytial virus, and other respiratory infections; as well as inhalers and other device therapies. The journal is of interest to a wide audience of pharmaceutical and healthcare professionals and publishes original research, reviews, case reports/series, trial protocols, and short communications such as commentaries and editorials. Pulmonary Therapy welcomes all scientifically sound research, whether it presents positive, confirmatory, or negative data. Submissions are encouraged whether they target an international or country-specific audience, which is crucial when researchers aim to address more specific patient populations. This inclusive approach allows the journal to assist in disseminating quality research that may be considered of insufficient interest by other journals. The journal aims for rapid publication timelines, targeting a peer review period of two weeks. If an article is accepted, it will be published within 3-4 weeks from acceptance. These rapid timelines are achieved through a dedicated in-house editorial team that manages article workflow and an extensive Editorial and Advisory Board that assists with peer review. This enables the journal to support the rapid dissemination of research while still providing robust peer review. Combined with the journal’s open access model, this allows for the swift and efficient communication of the latest research and reviews, fostering the advancement of pulmonary therapies. All articles published by Pulmonary Therapy are open access. The journal’s dedicated in-house editorial team offers a personal “concierge service,” meaning authors will always have an editorial contact to update them on the status of their manuscript. The editorial team checks all manuscripts to ensure that articles conform to the most recent COPE, GPP, and ICMJE publishing guidelines. This supports the publication of ethically sound and transparent research. Pulmonary Therapy offers a range of additional features designed to increase the visibility, readership, and educational value of the journal’s content. Each article is accompanied by key summary points, providing a time-efficient overview of the content for a wide readership. Articles may also include plain language summaries to help readers with some knowledge but not in-depth expertise in the area understand the scientific content and overall implications of the article. The journal also provides options to include various types of digital features, including animated abstracts, video abstracts, slide decks, audio slides, instructional videos, infographics, podcasts, and animations. All additional features are peer-reviewed to the same high standard as the article itself. If you believe your paper would benefit from the inclusion of a digital feature, please let us know. Our editorial team can create high-quality slide decks and infographics in-house and produce video abstracts through our partner Research Square, and we would be happy to assist in any way we can. For further information about digital features, please contact the journal editor (see ‘Contact the Journal’ for email address), and refer to the ‘Guidelines for digital features and plain language summaries’ document under ‘Submission guidelines.’ Upon acceptance of an article, authors will be required to pay the mandatory Rapid Service Fee of €4500/$5100/£3650. The journal will consider fee discounts and waivers for developing countries on a case-by-case basis. Upon submission, manuscripts are assessed by the editorial team to ensure they fit within the aims and scope of the journal and are also checked for plagiarism. All suitable submissions undergo a comprehensive single-blind peer review. Reviewers are selected based on their relevant expertise and publication history in the subject area. The journal has an extensive pool of editorial and advisory board members who have been selected to assist with peer review based on the aforementioned criteria. At least two extensive reviews are required to make the editorial decision, with the exception of some article types such as Commentaries, Editorials, and Letters, which are generally reviewed by one member of the Editorial Board. Where reviewer recommendations conflict, the editorial board will be contacted for further advice and a presiding decision. Manuscripts are then either accepted, rejected, or authors are required to make major or minor revisions (both reviewer comments and editorial comments may need to be addressed). Once a revised manuscript is re-submitted, it is assessed along with the responses to reviewer comments, and if it has been adequately revised, it will be accepted for publication. Accepted manuscripts are then copyedited and typeset by the production team before online publication. Appeals against decisions following peer review are considered on a case-by-case basis and should be sent to the journal editor. We encourage the posting of preprints of primary research manuscripts on preprint servers, authors’ or institutional websites, and open communications between researchers, whether on community preprint servers or preprint commenting platforms. Posting of preprints is not considered prior publication and will not jeopardize consideration in our journals. Authors should disclose details of preprint posting during the submission process or at any other point during consideration in one of our journals. Once the manuscript is published, it is the author’s responsibility to ensure that the preprint record is updated with a publication reference, including the DOI and a URL link to the published version of the article on the journal website. For further information on preprint sharing, please follow the link. The content of Pulmonary Therapy is published open access under the Creative Commons Attribution-Noncommercial License, which allows users to read, copy, distribute, and make derivative works for non-commercial purposes from the material, as long as the author of the original work is cited. The author assigns the exclusive right to any commercial use of the article to Springer. For more information about the Creative Commons Attribution-Noncommercial License, click here. For more information about the journal, including pre-submission inquiries, please contact christopher.vautrinot@springer.com.

《Pulmonary Therapy》是一本国际性的开放获取、同行评审（单盲）和快速出版的期刊。期刊的范围广泛，接受所有科学上合理的研究，包括临床前研究、临床研究（各个阶段）、观察性研究、真实世界研究以及与肺部治疗、设备和外科技术相关的健康结果研究。期刊关注的领域包括但不限于：哮喘；慢性阻塞性肺病；特发性肺纤维化；肺动脉高压；囊性纤维化；肺癌；呼吸道疾病；过敏性鼻炎及其他呼吸道过敏；流感、肺炎球菌感染、呼吸道合胞病毒及其他呼吸道感染；以及吸入器和其他设备治疗。期刊的受众广泛，涵盖制药和医疗专业人员，发表原创研究、综述、病例报告/系列、试验方案以及简短的通讯，如评论和社论。《Pulmonary Therapy》欢迎所有科学上合理的研究，无论是正面、确认性或负面数据。无论研究是否针对国际或特定国家的受众，均可提交，这在研究者试图针对更特定的患者群体时尤为重要。这种包容性的方法使期刊能够帮助传播质量研究，这些研究可能被其他期刊认为兴趣不足。期刊的出版时间目标是实现快速同行评审，通常为两周。如果文章被接受，通常会在接受后3-4周内出版。快速的时间表得益于专门的内部编辑团队，他们管理文章的工作流程，以及广泛的编辑和顾问委员会，他们协助同行评审。这使期刊能够支持研究的快速传播，同时仍提供稳健的同行评审。结合期刊的开放获取模式，这使得最新的研究和综述能够快速、高效地传播，促进肺部治疗的进步。所有发表在《Pulmonary Therapy》上的文章均为开放获取。期刊的专门内部编辑团队提供个人“礼宾服务”，意味着作者始终可以联系到编辑，了解手稿的状态。编辑团队会检查所有手稿，以确保文章符合最新的COPE、GPP和ICMJE出版指南。这支持了伦理上合理和透明的研究的出版。期刊提供一系列额外功能，旨在提高期刊内容的可见性、可读性和教育价值。每篇文章都附有关键摘要，提供内容的高效概述，便于广泛读者理解。文章可能附有通俗语言摘要，帮助对该领域有一定了解但没有深入专业知识的读者理解科学内容及其整体影响。期刊还提供包括动画摘要、视频摘要、幻灯片、音频幻灯片、教学视频、信息图、播客和动画等各种数字功能的选项。所有附加功能均经过与文章本身相同的高标准同行评审。如果您认为您的论文可以受益于数字功能的包含，请告知我们。我们的编辑团队能够在内部创建高质量的幻灯片和信息图，并通过我们的合作伙伴Research Square制作视频摘要，乐意提供任何帮助。有关数字功能的更多信息，请联系期刊编辑（请参见“联系期刊”中的电子邮件地址），并查看“提交指南”下的“数字功能和通俗语言摘要指南”文档。接受文章后，作者需支付强制性的快速服务费€4500/$5100/£3650。期刊将根据具体情况考虑对发展中国家的费用折扣和豁免。提交后，手稿由编辑团队评估，以确保其符合期刊的目标和范围，并检查抄袭。所有合适的提交将接受全面的单盲同行评审。审稿人根据其相关专业知识和出版历史进行选择。期刊拥有广泛的编辑和顾问委员会成员，已根据上述标准进行选择。至少需要两次详细审查以做出编辑决定，某些文章类型（如评论、社论和信件）通常仅由一名编辑委员会成员审查。如果审稿人建议存在冲突，编辑委员会将被联系以获取进一步建议和最终决定。手稿随后被接受、拒绝或要求作者进行重大或小修。修订后的手稿重新提交后，将与审稿人意见的回应一起进行评估，如果已充分修订，将被接受出版。被接受的手稿随后由制作团队进行校对和排版，然后在线发布。对同行评审后决定的上诉将根据具体情况进行考虑，并应发送给期刊编辑。我们鼓励在预印本服务器、作者或机构网站上发布初步研究手稿的预印本，并在研究人员之间进行开放交流，无论是在社区预印本服务器还是预印本评论平台上。发布预印本不被视为先前出版，不会影响在我们期刊中的考虑。作者应在提交过程中或在考虑的任何其他时刻披露预印本发布的详细信息。手稿发表后，作者有责任确保预印本记录更新为出版参考，包括DOI和指向期刊网站上已发表版本的URL链接。有关预印本共享的更多信息，请访问链接。 《Pulmonary Therapy》的内容在知识共享署名-非商业性使用许可下开放获取，允许用户在引用原作者的情况下，阅读、复制、分发和制作衍生作品。作者将文章的商业使用独占权转让给Springer。有关知识共享署名-非商业性使用许可的更多信息，请点击此处。有关期刊的更多信息，包括预提交查询，请联系christopher.vautrinot@springer.com。

Εosinophilic Chronic Obstructive Pulmonary Disease. What Do We Know So Far?

ivySCI AI Smartly Parses PDF, Answers Researchers' Questions, and Helps You Understand Papers in Seconds

Journal Info

Category	Quartile
RESPIRATORY SYSTEM	2